Cough, Cold and Allergy (Hay Fever) Remedies in the US

In 2011, Chattem Inc’s Allegra brand of antihistamine/allergy remedies (systemic) switched from Rx-to-OTC, representing one of the largest switches in the segment’s history. First stocked on store shelves in March, Chattem accompanied Allegra’s launch with significant promotional spending both in-store and via media outlets. Attractive end-caps and displays at major retailers heralded the brand’s switch, while television and online advertisements appeared with great frequency. With its switch...

Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.

Product coverage: Antihistamines/Allergy Remedies (Systemic), Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies, Cough Remedies, Decongestants, Medicated Confectionery, Paediatric Cough, Cold and Allergy Remedies, Pharyngeal Preparations.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.